Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBD Inspire Corporate Bond ETF

休市中 08-23 16:00:00 EDT

24.04

+0.08

+0.33%

最高24.10	最低23.94	成交量3.38万
今开23.94	昨收23.96	日振幅0.67%
总市值3.58亿	流通市值3.58亿	总股本1,490万
成交额81.31万	换手率0.23%	流通股本1,490万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.04,"timestamp":1724443200000,"preClose":23.96,"halted":0,"volume":33804,"delay":0,"floatShares":14900000,"shares":14900000,"eps":0,"marketStatus":"休市中","marketStatusCode":7,"change":0.08,"latestTime":"08-23 16:00:00 EDT","open":23.94,"high":24.1,"low":23.94,"amount":813084.096384,"amplitude":0.006678,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"exchange":"ARCA","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":0,"adjPreClose":23.96,"adrRate":0,"sharesOutstanding":15000000,"nav":23.99,"aum":359803999.38,"bidAskSpread":0.003058,"volumeRatio":0.6017280710627138},"requestUrl":"/m/hq/s/IBD/wiki","defaultTab":"wiki","newsList":[{"id":"2450082641","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2450082641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450082641?lang=zh_cn&edition=full","pubTime":"2024-07-09 03:59","pubTimestamp":1720468795,"startTime":"0","endTime":"0","summary":"     路透7月8日 - 截至格林尼治标准时间周一19 时 45分，报导了以下竞购、兼并、收购和处置活动：** 巴西物流公司Transpetro是国营石油公司Petrobras  旗下的一个部门，该公司称已发布采购公告，将委托建造四艘新的沿海船舶，希望这将有助于重振巴西的造船业。**Masimo   称，一家潜在的合资伙伴准备出价8.5亿至9.5亿美元收购其消费者业务，其中包括健康和音频产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD"],"gpt_icon":0},{"id":"2449709515","title":"深夜！突然暴涨75%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2449709515","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449709515?lang=zh_cn&edition=full","pubTime":"2024-07-08 22:13","pubTimestamp":1720447993,"startTime":"0","endTime":"0","summary":"一则重磅收购引发医药圈震动。北京时间7月8日晚间，美股开盘后，美国生物制药公司Morphic股价一度暴涨超75%。消息面上，生物医药巨头礼来公司官宣，将以57美元/股的价格现金收购Morphic，较上周五的收盘价溢价79%，该交易预计将于2024年第三季度完成。分析人士指出，礼来公司高溢价收购Morphic的主要意图，或许是为了加码IBD（炎症性肠病）赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407083124868778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBD"],"gpt_icon":0},{"id":"2448440442","title":"自免领域频频“加码”，艾伯维再花2.5亿美元寻合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2448440442","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448440442?lang=zh_cn&edition=full","pubTime":"2024-07-04 20:45","pubTimestamp":1720097100,"startTime":"0","endTime":"0","summary":"艾伯维在自身免疫性疾病领域又出手了，近日收购了私营生物科技公司Celsius Therapeutics，收购后者所有流通股股权花费2.5亿美元。自免领域频出手根据收购协议的相关条款，艾伯维以2.5亿美元的现金收购了Celsius公司的所有流通股股权，最终支付金额将视行业惯例做出相应调整。作为全球最畅销药物，过去20多年来，修美乐已经为艾伯维带来超过2000亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240704204628af909576&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240704204628af909576&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1732799900.SGD","LU0882574055.USD","LU1267930490.SGD","BK4566","LU0122379950.USD","LU0211328371.USD","IE00BJJMRZ35.SGD","BK4139","BK4588","LU0820561909.HKD","IE0009355771.USD","LU1093756325.SGD","LU1496350171.SGD","LU0456855351.SGD","LU0029864427.USD","BK4550","LU0170899867.USD","LU0795875086.SGD","LU0985320562.USD","LU1244550494.USD","IE00B2B36J28.USD","LU1267930573.SGD","IE0004445239.USD","BK4559","IE0002141913.USD","LU0198837287.USD","LU0310800379.SGD","LU0114720955.EUR","LU0689472784.USD","LU0795875169.SGD","BK4585","LU0211327993.USD","LU1551013425.SGD","LU0256863811.USD","LU0708994859.HKD","LU1718418525.SGD","ABBV","IBD","BK4581","LU0943347566.SGD","LU0820561818.USD","LU1551013342.USD","LU0949170772.SGD","LU1430594728.SGD","LU1496350502.SGD","IE00BFTCPJ56.SGD","LU1244550221.USD","LU0310799852.SGD","LU0234570918.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2448245275","title":"医药行业周报：艾伯维以2.5亿美元收购CELSIUS","url":"https://stock-news.laohu8.com/highlight/detail?id=2448245275","media":"太平洋证券股份...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448245275?lang=zh_cn&edition=full","pubTime":"2024-07-04 00:00","pubTimestamp":1720022400,"startTime":"0","endTime":"0","summary":"行业要闻：6 月28 日， 艾伯维宣布以2.5 亿美元款项收购CelsiusTherapeutics。TREM1 已被确认为IBD 中的关键致病基因，主要表达于炎性单核细胞和中性粒细胞上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040810449eff51d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040810449eff51d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0211328371.USD","BK4566","BK4585","LU0211327993.USD","BK4534","LU1267930490.SGD","LU0128525929.USD","IE00BJT1NW94.SGD","LU0795875169.SGD","BK4550","LU1496350502.SGD","BK4581","LU1267930573.SGD","LU1551013342.USD","IE0004445239.USD","IE0002141913.USD","LU1244550494.USD","LU0310799852.SGD","ABBV","IE00BJJMRZ35.SGD","LU0882574055.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1430594728.SGD","LU0198837287.USD","LU0943347566.SGD","IBD","LU0310800379.SGD","LU1496350171.SGD","LU1093756168.USD","LU0170899867.USD","LU0256863811.USD","LU0820561818.USD","LU0820561909.HKD","LU0708994859.HKD","LU1551013425.SGD","IE0009355771.USD","LU1732799900.SGD","LU1244550221.USD","CELH","BK4533","BK4588","BK4139","BK4559","LU1093756325.SGD","LU0114720955.EUR","LU1718418525.SGD","LU0689472784.USD","LU0456855351.SGD","LU0985320562.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"2446077585","title":"【艾伯维(ABBV.US)2.5亿美元达成收购协议 囊获潜在“first-in-class”疗法】智通财经APP获悉，近日艾伯维(ABBV.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446077585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446077585?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:09","pubTimestamp":1719580178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0114720955.EUR","LU1496350171.SGD","LU0310799852.SGD","LENZ","LU0029864427.USD","IBD","LU0943347566.SGD","LU1551013342.USD","LU0795875169.SGD","LU0234572021.USD","IE00BJJMRZ35.SGD","IE0004445239.USD","LU0417517546.SGD","LU1551013425.SGD","BK4585","LU0211327993.USD","LU0234570918.USD","IE00BJT1NW94.SGD","LU1732799900.SGD","BK4566","LU0158827948.USD","IE0002141913.USD","BK4139","BK4581","LU0211328371.USD","LU1585245621.USD","LU1244550577.SGD","LU0122379950.USD","LU0256863811.USD","BK4550","LU1291159041.SGD","LU0128525929.USD","LU0738911758.USD","LU1057294990.SGD","LU1023059063.AUD","LU1267930573.SGD","LU1093756325.SGD","LU0912757837.SGD","BK4588","LU1732800096.USD","LU1093756168.USD","LU0820561909.HKD","IE00BSNM7G36.USD","BK4559","LU0661504455.SGD","LU1244550221.USD","ABBV","LU0310800379.SGD","LU0708994859.HKD","LU0882574055.USD"],"gpt_icon":0},{"id":"2444055651","title":"124亿元布局候选药物 TL1A靶点何以让艾伯维心动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2444055651","media":"每经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444055651?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:13","pubTimestamp":1718698430,"startTime":"0","endTime":"0","summary":"6月13日，明济生物宣布将临床前TL1A抗体FG-M701的全球权益授权给艾伯维，艾伯维支付1.5亿美元预付款和近期里程碑付款，以及15.6亿美元里程碑金额，低两位数比例的销售分成。艾伯维一直以来深耕自免赛道，斥资124亿元只为获得一款临床前候选药物的全球权益，靶点TL1A何以让艾伯维心动？布局TL1A靶点的MNC中，艾伯维可以在全球进行开发、生产和商业化FG-M701的独家许可权，包括中国在内。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061816143795bcd134&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061816143795bcd134&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0211328371.USD","BK4566","BK4585","LU0211327993.USD","LU1057294990.SGD","LU0661504455.SGD","LU1267930490.SGD","LU0128525929.USD","IE00BJT1NW94.SGD","LU0795875169.SGD","BK4550","LU1551013342.USD","BK4116","BK4581","LU1267930573.SGD","IE0004445239.USD","IE0002141913.USD","LU0310799852.SGD","ABBV","IE00BJJMRZ35.SGD","CD","LU0882574055.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0198837287.USD","LU0943347566.SGD","IBD","LU0310800379.SGD","LU1496350171.SGD","LU1093756168.USD","LU0170899867.USD","LU0256863811.USD","LU0820561818.USD","LU0820561909.HKD","LU0708994859.HKD","LU1551013425.SGD","LU1585245621.USD","IE0009355771.USD","LU1732799900.SGD","LU1244550221.USD","BK4588","BK4139","BK4559","LU1093756325.SGD","LU1732800096.USD","LU0114720955.EUR","LU0689472784.USD","LU1244550577.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2443493665","title":"17.1亿美元！艾伯维引进明济生物临床前TL1A单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2443493665","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443493665?lang=zh_cn&edition=full","pubTime":"2024-06-14 08:14","pubTimestamp":1718324050,"startTime":"0","endTime":"0","summary":"6月13日，艾伯维宣布与明济生物签署了一项许可协议，将共同开发一款处于临床前开发阶段的用于治疗炎症性肠病的下一代TL1A抗体FG-M701。根据协议条款，艾伯维将获得FG-M701在全球进行开发、生产和商业化的独家许可权。FG-M701是一种靶向TL1A的全人源单克隆抗体，是经临床验证的炎症性肠病的靶点。目前，明济生物利用STEP平台开发了ADCC增强型CLDN18.2单抗FG-M108。此外，明济生物还拥有一系列用于肿瘤免疫治疗的创新多特异性抗体和ADC药物，包括CD40/PDL1双特异性抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406140820459f3aa8d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406140820459f3aa8d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1496350171.SGD","LU0128525929.USD","LU1244550494.USD","LU1267930573.SGD","LU0198837287.USD","LU1496350502.SGD","IE00B2B36J28.USD","IE0004445239.USD","IE0002141913.USD","LU1718418525.SGD","LU0122379950.USD","LU1093756168.USD","LU1732799900.SGD","IE00BFTCPJ56.SGD","LU0689472784.USD","LU1057294990.SGD","LU0985320562.USD","BK4550","BK4533","ABBV","BK4585","LU0114720955.EUR","BK4588","LU0211328371.USD","LU0708994859.HKD","IE0009355771.USD","LU1244550221.USD","LU1267930490.SGD","LU1093756325.SGD","BK4139","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU0882574055.USD","BK4534","IE00BJT1NW94.SGD","IBD","BK4559","LU0310800379.SGD","LU0256863811.USD","LU0820561909.HKD","LU1551013425.SGD","LU0795875169.SGD","BK4566","LU0170899867.USD","LU1551013342.USD","LU0211327993.USD","LU0310799852.SGD","LU1430594728.SGD","LU0456855351.SGD","LU0820561818.USD"],"gpt_icon":0},{"id":"2443008085","title":"艾伯维与明济生物签署许可协议，共同开发下一代炎症性肠病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2443008085","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443008085?lang=zh_cn&edition=full","pubTime":"2024-06-13 20:21","pubTimestamp":1718281290,"startTime":"0","endTime":"0","summary":"艾伯维和明济生物制药(北京)有限公司宣布签署一项许可协议，共同开发FG-M701。FG-M701是正处于临床前开发阶段的一种用于治疗炎症性肠病(IBD)的下一代TL1A抗体。相较于第一代TL1A抗体，FG-M701具有潜在的成为同类最佳的功能特性，旨在为炎症性肠病治疗提供更佳的疗效并减少用药频率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613202145af8d6ab2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613202145af8d6ab2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1551013342.USD","LU0708994859.HKD","IE0009355771.USD","BK4566","IE00BSNM7G36.USD","LU0820561909.HKD","LU0949170772.SGD","LU1267930573.SGD","LU1732799900.SGD","LU0795875169.SGD","IE0004445239.USD","BK4533","LU1496350171.SGD","BK4585","LU1244550494.USD","BK4550","LU0820561818.USD","IE0002141913.USD","LU0170899867.USD","LU0456855351.SGD","LU1244550221.USD","LU0198837287.USD","BK4559","LU0310799852.SGD","LU1551013425.SGD","LU0122379950.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU1718418525.SGD","LU0114720955.EUR","IBD","LU0985320562.USD","LU1267930490.SGD","LU0234570918.USD","LU1430594728.SGD","LU1496350502.SGD","LU0128525929.USD","BK4534","LU0795875086.SGD","LU0029864427.USD","LU0211328371.USD","LU0943347566.SGD","LU0689472784.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","ABBV","LU1093756325.SGD","LU0310800379.SGD","LU0211327993.USD"],"gpt_icon":0},{"id":"2443500894","title":"艾伯维和明济生物制药（北京）有限公司宣布签署一项许可协议共同开发FG-M701。FG-M701是正处于临床前开发阶段的一种用于治疗炎症性肠病（IBD）的下一代TL1A抗体。","url":"https://stock-news.laohu8.com/highlight/detail?id=2443500894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443500894?lang=zh_cn&edition=full","pubTime":"2024-06-13 20:20","pubTimestamp":1718281230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBD","FG","BK4162"],"gpt_icon":0},{"id":"2441291397","title":"健康巡讲：未经治疗的心房颤动会增加痴呆症和死亡的风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2441291397","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441291397?lang=zh_cn&edition=full","pubTime":"2024-06-07 03:26","pubTimestamp":1717701981,"startTime":"0","endTime":"0","summary":"未经治疗的心律失常与痴呆症的高风险有关英国一项大型研究显示，患有常见心律失常的心房颤动患者如果不服用可降低中风风险的血液稀释剂，患痴呆症和死亡的风险也会更高。这组患者在研究期间的死亡风险也高出44%，患血管性痴呆的风险高出68%。研究人员指出，这项研究并不是为了证明未经治疗的阿非布会导致这些结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","IE00B2B36J28.USD","LU1670711040.USD","LU1732800096.USD","BK4568","IBD","LU2347655156.SGD","LU0170899867.USD","LU1023059063.AUD","LU2360032135.SGD","LU1032466523.USD","IE00BLSP4452.SGD","LU0912757837.SGD","LU2125154935.USD","LU1430594728.SGD","LU0795875086.SGD","LU1196500208.SGD","IE00B19Z3581.USD","LU0234572021.USD","LU1032955483.USD","LU1267930813.SGD","BK4585","LU2125154778.USD","IE00BSNM7G36.USD","LU1244550577.SGD","SG9999013999.USD","LU0640476718.USD","LU1221951046.USD","LU0289739699.SGD","BK4559","BK4588","LU1059921491.USD","LU1244550494.USD","LU1291159041.SGD","LU1585245621.USD","LU1718418525.SGD","LU2133065610.SGD","LU2602419157.SGD","SG9999002224.SGD","LU0456855351.SGD","PFE","BMY","BK4592","SG9999001440.SGD","SG9999002232.USD","LU2242646821.SGD","LU0889566641.SGD","LU0321505439.SGD","LU1221951129.SGD","JNJ"],"gpt_icon":0},{"id":"2419154799","title":"成立2年、市值40亿美元，一场有预谋的“生物科技实验”","url":"https://stock-news.laohu8.com/highlight/detail?id=2419154799","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2419154799?lang=zh_cn&edition=full","pubTime":"2024-03-15 11:45","pubTimestamp":1710474319,"startTime":"0","endTime":"0","summary":"成立仅7个月，顺利IPO；资本寒冬，IPO超募3亿美元；上市仅9个月，股价涨幅311%，市值达到40亿美元。你很难想象，这些战绩，都是一家核心管线均处于临床前biotech，Apogee创造的。当然，一切并非毫无迹象可循。癌症之外，市场对于自免热度极高。近两年，大额并购案不断，度普利尤单抗的持续进击，更是刺激着市场的神经。而A...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OkdvF_twBk4b7b16ikTeHgqBhs7N1g4u-3_NgrQF_09JgAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OkdvF_twBk4b7b16ikTeHgqBhs7N1g4u-3_NgrQF_09JgAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240315A03GJL00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240315A03GJL00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["IBD"],"gpt_icon":0},{"id":"2413276427","title":"世纪大战，最后生还者","url":"https://stock-news.laohu8.com/highlight/detail?id=2413276427","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2413276427?lang=zh_cn&edition=full","pubTime":"2024-02-23 07:46","pubTimestamp":1708645611,"startTime":"0","endTime":"0","summary":"随着GLP-1长效减肥药进入商业化阶段，以及监管风格趋严，继PD-1之后中国创新药最大的泡沫将开始破灭。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/a02a02af-139b-4060-90f3-c36eab4177ca.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/a02a02af-139b-4060-90f3-c36eab4177ca.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3708864","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3708864","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["01801","BK4160","IBD","BK1161","BK1589","LU1969619763.USD","GIPR","BK1583","LU2328871848.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inspireetf.com/etf/inspire-corporate-bond-impact-etf/","stockEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":0.023},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0298},{"period":"1year","weight":0.0498},{"period":"ytd","weight":0.0191}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.001547},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.008847},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.010287},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.000391},{"month":5,"riseRate":0.857143,"avgChangeRate":0.006486},{"month":6,"riseRate":0.571429,"avgChangeRate":0.001217},{"month":7,"riseRate":0.857143,"avgChangeRate":0.007001},{"month":8,"riseRate":0.5,"avgChangeRate":0.001145},{"month":9,"riseRate":0,"avgChangeRate":-0.011447},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004183},{"month":11,"riseRate":0.428571,"avgChangeRate":0.007875},{"month":12,"riseRate":0.428571,"avgChangeRate":0.00414}],"exchange":"ARCA","name":"Inspire Corporate Bond ETF","nameEN":"Inspire Corporate Bond ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inspire Corporate Bond ETF,IBD,Inspire Corporate Bond ETF股票,Inspire Corporate Bond ETF股票老虎,Inspire Corporate Bond ETF股票老虎国际,Inspire Corporate Bond ETF行情,Inspire Corporate Bond ETF股票行情,Inspire Corporate Bond ETF股价,Inspire Corporate Bond ETF股市,Inspire Corporate Bond ETF股票价格,Inspire Corporate Bond ETF股票交易,Inspire Corporate Bond ETF股票购买,Inspire Corporate Bond ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}